Jim Woodward is a Sector Specialist in the Healthcare practice at Daybreak Capital Partners. Mr. Woodward is also a Principal at TCG, a business development and interim management consulting firm specializing in medical devices, diagnostics and biotechnology.
Mr. Woodward has spent over 25 years in early-stage medical device, diagnostic and healthcare service companies with strong experience in financial direction, general management, M&A/licensing, and product development strategy. He was most recently President & CEO of Encelle Inc., a venture-backed developer of tissue-regenerative biopolymers, acquired by Pioneer Surgical Technology.
Earlier in his career, Mr. Woodward was a Co-founder, Director, and acting CFO in the early years of Accordant Health Services. He also served as acting Chairman & CEO of Aprex Corporation and as President & CEO of Cardiometrics. Earlier in his career, Mr. Woodward was CFO and Director of Advanced Cardiovascular Systems, Inc. (acquired by Eli Lilly, now Abbott Vascular). He was a Co-founder and Director of Interventional Technologies (acquired by Boston Scientific) and Ventana Medical Systems (acquired by Roche).
Mr. Woodward began his business career as a management consultant with McKinsey & Company. He holds an A.B. in economics from Princeton University and an M.B.A. from Stanford University Graduate School of Business.